SYDNEY, Australia – 4 June 2019 –Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced positive data from the ongoing patients in the Phase Ib study of its HER-Vaxx cancer vaccine was presented at the prestigious American Society of Clinical Oncology (ASCO) annual meeting in Chicago Illinois, USA 31 May to 3 June 2019. The abstract (number 4030) was presented by Dr Yee Chao, Director of the Department of Oncology at the Veterans GeneralHospital in Taipei, Taiwan and a lead investigator in the Phase 1b study and was featured at the ASCO Gastrointestinal (Noncolorectal) Cancer Session on Monday 3 June between 8:00am and 11:00am. The Phase 1b HER-Vaxx study which completed enrolment in 2018 met all its primary endpoints. The study is ongoing with patients continuing to receive HER-Vaxx every 3 months to maintain high levels of cancer targeting antibodies. A Phase 2 study was initiated in March 2019 dosing patients at the highest Phase 1b dose. The presentation details the continued progress being made by patients who received the highest dose of HER-Vaxx. By day 182 of the trial, their tumours have either shrunk further or stabilized. In one patient, their tumour has shrunk more than 70% since joining the trial. All patients on the highest dose have already received their day 266 doses and these results will be presented in an oral presentation at ESMO GI in Barcelona on 3-6 July 2019. The presentation is entitled: ‘A phase Ib study of IMU-131 HER2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction.’ The ASCO annual meeting attracts more than 40,000 cancer specialists and is one of the largest educational and scientific events in the oncology community where the latest research and clinical results are highlighted. Imugene Managing Director and Chief Executive Officer Leslie Chong said, “There is continued interest in the positive data from our Phase Ib trial which supports our B-cell platform cancer vaccine strategy for treating HER-2 positive gastric cancer.” The full presentation is available on the Imugene website. |